If you’re looking into a metoprolol recall lawsuit, here is the short version: two class actions over metoprolol succinate have been resolved, and no active personal injury class action tied to the recalled tablets appears on the public record as of mid-2026. One case, an antitrust suit against AstraZeneca, paid consumers and insurers through an $11 million settlement and paid direct purchasers through a separate $20 million settlement. The other, against generic maker KV Pharmaceutical, was revived on appeal in 2011, and the file carries no published final verdict or settlement for it. Recalls for failed dissolution testing have continued into 2026, but recalls on their own do not create a lawsuit you can join.
Why Metoprolol Keeps Getting Recalled
Metoprolol succinate is the extended-release beta-blocker sold under the brand name Toprol XL. The tablet is engineered to release the drug slowly across 24 hours so one daily dose keeps blood pressure and heart rate steady. When a batch fails dissolution testing, the tablet may not release its active ingredient on schedule, which can leave a patient effectively under-dosed without any obvious warning sign.
The FDA has classified every dissolution-failure recall in the available record as Class II, meaning the product “may cause temporary or medically reversible adverse health consequences” but serious harm is unlikely. The practical worry is less a single bad pill than weeks or months of tablets that aren’t working the way the prescription assumes. Patients should not stop a beta-blocker abruptly on their own; rebound effects can be dangerous.
The AstraZeneca Settlements: Where Consumers Were Actually Paid
Two consolidated class actions were filed in the U.S. District Court for the District of Delaware before Judge Gregory M. Sleet, docketed as Civil Action Nos. 06-52 and 06-71. The plaintiffs alleged that AstraZeneca fraudulently obtained two patents on Toprol XL (U.S. Patent Nos. 5,001,161 and 5,081,154) by withholding inventorship information from the Patent Office, listed those patents in the FDA’s Orange Book, and then sued generic challengers (including KV Pharmaceutical, Andrx Corp., and Sandoz) in what plaintiffs called “objectively baseless sham litigation” to trigger the Hatch-Waxman Act’s automatic 30-month stay on generic approvals. In July 2007 the Federal Circuit affirmed that the patents were invalid for double patenting, AstraZeneca did not appeal, and the underlying patent litigation was settled and dismissed in August 2008.
The End-Payor Settlement: $11 Million
The end-payor class covered anyone in the United States who purchased, paid for, or reimbursed others for Toprol XL or generic metoprolol succinate between May 5, 2005, and September 27, 2012. AstraZeneca denied wrongdoing. The claim-filing deadline was April 1, 2013, and settlement checks were mailed on November 22, 2013. Payouts varied based on how much each claimant spent and when. The claim window is long closed.
The Direct Purchaser Settlement: $20 Million
The direct purchaser class, represented by entities including Meijer, Inc. and Rochester Drug Co-Operative, reached a separate $20 million settlement that received court approval and resulted in a final judgment. This class covered pharmacies and wholesalers, not individual patients.
The KV Pharmaceutical Class Action
KV Pharmaceutical, through its subsidiaries Ethex and Ther-Rx, was an early generic manufacturer of metoprolol succinate. A proposed class action filed in federal court in St. Louis sought to represent any U.S. citizen who had consumed KV-manufactured metoprolol succinate tablets. The complaint pointed to an FDA inspection that identified more than 35 problems, including failures to keep equipment clean and to follow written production-control procedures, and alleged that KV had received FDA warnings after eight separate inspections between 2003 and 2009.
The district court initially dismissed the case. The Eighth Circuit reversed in early 2011, reviving the class action, and on May 11, 2011, declined KV’s request for rehearing. The available record does not contain a published final outcome, such as a verdict or settlement, for the KV class action.
The Recall History a Lawsuit Would Draw On
Dissolution failures in generic metoprolol succinate are not a one-off. If you’re trying to figure out whether a bottle you were dispensed is part of a recall, these are the events in the file.
2014
In May 2014, Dr. Reddy’s Laboratories recalled 13,560 bottles of generic metoprolol succinate extended-release tablets after a failed dissolution test. Around the same time, Wockhardt voluntarily recalled nearly 110,000 bottles of its 50 mg tablets for failing nine-month dissolution specifications. Both recalls were Class II. The FDA by then had received thousands of complaints about generic metoprolol, including from Cleveland Clinic cardiologist Dr. Harry Lever, who reported patients developing chest pains after switching from brand-name Toprol XL.
2025
In June 2025, Granules India recalled more than 33,000 bottles of its 25 mg extended-release tablets after a six-month stability test failure; affected lots carried a December 2025 expiration. In August 2025, Westminster Pharmaceuticals recalled more than 21,000 bottles of metoprolol tartrate (the immediate-release form, not the extended-release succinate) in 50 mg and 100 mg strengths because of contamination with N-nitroso-metoprolol above the acceptable daily intake. Both were Class II.
2026
On March 10, 2026, the FDA posted a Class II recall of 112,327 bottles of Teva-manufactured metoprolol succinate extended-release tablets across all four strengths (25 mg, 50 mg, 100 mg, and 200 mg) for failed dissolution. Twenty-one lots were affected, with expirations from December 2026 through February 2027. Teva’s own health-hazard assessment called the likelihood of harm “remote” and the overall risk “low,” and the company did not issue a press release.
In April 2026, Ascend Laboratories voluntarily recalled 17,304 bottles of its 25 mg extended-release tablets (lot 25140859) after testing showed accelerated drug release at the eight-hour time point. Ascend described the deviation as “not expected to be clinically significant.” The FDA classified it as Class II in the enforcement report dated May 20, 2026.
If You Have a Recalled Bottle
Check the lot number printed on the bottle against the FDA enforcement report for the recall that matches your manufacturer. Call your pharmacist or prescriber to arrange a replacement supply; do not stop the drug on your own. Report any adverse effects to the FDA’s MedWatch program at 1-800-FDA-0178. For questions specific to the Teva recall, the company’s medical-information line is 1-888-838-2872.
On the legal side, some plaintiff firms have advertised consultations for people who believe they were harmed by recalled metoprolol, but the available record does not show pending cases with named plaintiffs or class certifications tied to patient injuries from the recalled lots. The two class actions that did move forward (the KV manufacturing-defect case and the AstraZeneca antitrust case) addressed company conduct, not individual medical harm, and the AstraZeneca consumer claim window closed in 2013.